chadox1.hti
Vaccineexperimental
Clinical trial activity
4 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 7, 2017 (NCT03204617)
Timeline
Indications
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05208125 | Phase 1 | Mar 30, 2022 | Badalona Hospital Germans Trias i Pujol, IrsiCaixa, University of Texas at Houston |
| NCT04563377 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2020 | University of Oxford |
| NCT04364035 | Phase 2 | Feb 20, 2020 | Aelix Therapeutics, Autonomous University of Madrid, Gilead Sciences |
| NCT03204617 | Phase 1 | Jul 7, 2017 | Aelix Therapeutics |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aelix Therapeutics | For profit | 2 | 2 | 2 | 2017 |
| Autonomous University of Madrid | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Badalona Hospital Germans Trias i Pujol | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Gilead Sciences | For profit | 1 | 0 | 1 | 2020 |
| IrsiCaixa | Academic/Hospital | 1 | 1 | 1 | 2022 |
| University of Oxford | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2022 |
7 organizations
Page 1 / 1